High rates of susceptibility to ceftazidime among globally prevalent CTX-M-producing Escherichia coli: Potential clinical implications of the revised CLSI interpretive criteria

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 5, 2012, Pages 821-824

  Williamson, D A ^a   Roberts, S A ^a   Smith, M ^a   Heffernan, H ^b   Tiong, A ^a   Pope, C ^b   Freeman, J T ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 14; BETA LACTAMASE CTX M 15; CEFTAZIDIME; CEFTRIAXONE; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEFTAZIDIME; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84862882627     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1380-1     Document Type: Article

References (14)

1. Bonnet R (2004) Growing group of extended-spectrum β- lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 48: 1-14
2. Peirano G, Pitout JD (2010) Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25: H4. Int J Antimicrob Agents 35: 316-321
3. Lewis JS, Herrera M, Wickes B, Patterson JE, Jorgensen JH (2007) First report of the emergence of CTX-M-type extendedspectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 51: 4015-4021
4. McGettigan SE, Hu B, Andreacchio K, Nachamkin I, Edelstein PH (2009) Prevalence of CTX-M β-lactamases in Philadelphia, Pennsylvania. J Clin Micro 47: 2970-2974
5. Clinical and Laboratory Standards Institute (CLSI) (2010) Performance standards for antimicrobial susceptibility testing; CLSI document M100-S20. CLSI, Wayne, PA
6. Song W, Bae IK, Lee YN et al (2007) Detection of extendedspectrum β-lactamases by using boronic acid as an AmpC β- lactamase inhibitor in clinical isolates of Klebsiella spp. And Escherichia coli. J Clin Microbiol 45(4): 1180-4
7. Jeong SH, Bae IK, Kwon SB et al (2005) Dissemination of transferable CTX-M-type extended-spectrum β-lactamaseproducing Escherichia coli in Korea. J Appl Microbiol 98: 921-7
8. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrobial wild type distributions of microorganisms. Home page at: http: //www.escmid.org
9. Gniadkowski M (2008) Evolution of extended-spectrum β- lactamases by mutation. Clin Microbiol Infect 14(Suppl 1): 11-32
10. Andes D, Craig WA (2005) Treatment of infections with ESBLproducing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 11(Suppl 6): 10-17
11. Turnidge J, Paterson DL (2007) Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 20: 391-408
12. Roberts JA, Kirkpatrick CM, Lipman J (2011) Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother 66: 227-231
13. Tumbarello M, Sali M, Trecarichi EM et al (2008) Bloodstream infections caused by extended-spectrum-β-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 52: 3244-3252
14. Wong-Beringer A, Hindler J, Loeloff M et al (2002) Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 34(2): 135-146